Bhattacharya SK, Satyan KS, Chakrabarti A (1997) Anxiogenic action of caffeine: an experimental study in rats
Symptomatic management for mild injection site reactions includes: Applying a cool compress or ice pack wrapped in a thin cloth for 10 to 15 minutes to reduce swelling and discomfort Avoiding rubbing or massaging the injection site, which may increase irritation Using over-the-counter oral antihistamines (such as cetirizine or loratadine) for itching, if approved by a healthcare provider Applying fragrance-free, hypoallergenic moisturizer to dry or irritated skin around (not directly on) the injection site Patients should consult their healthcare provider before applying topical medications to injection sites, as these may mask signs of infection
Technical Specifications Compounds Included: GHK-Cu, BPC-157, TB-500 Total Peptide Content: 70 mg (50mg GHK-Cu, 10mg BPC-157, 10mg TB-500) Format: Lyophilized peptide blend Purity: 9899% (COA included) Appearance: Blue-tinted and white lyophilized peptide mixture Category: Research peptide reagent Intended Use Approved for: Laboratory experimentation In-vitro biochemical assays Multi-pathway mechanistic studies Preclinical, non-human research modeling Advanced peptide interaction analysis Academic or institutional research Not approved for: Human or veterinary consumption Injection, ingestion, inhalation, or topical application Cosmetic, dermatological, or therapeutic purposes Any clinical or medical application This product is not approved by FDA, Health Canada, or similar regulatory bodies for human use
Colorectal cancer (CRC) caused by a number of genetic disorders, including KRAS mutation, p53 mutation, and p53 depletion, which provides additional evidence for the survival-promoting function of p53
313610) or CD11b (1:250
